Opportunity
Simpler Grants.gov #RFA-MH-27-110
NIH Solicits Research on HIV Immunotherapies and CNS Outcomes
Buyer
National Institutes of Health
Posted
October 04, 2023
Respond By
October 22, 2026
Identifier
RFA-MH-27-110
NAICS
541715
The National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH), is seeking research proposals to study the effects of HIV immunotherapies on central nervous system (CNS) outcomes in people with HIV. - Government Buyer: - National Institutes of Health (NIH) - National Institute of Mental Health (NIMH) - Products/Services Requested: - Biphasic research services to evaluate the impact of HIV immunotherapies on CNS outcomes - Focus on mechanisms, benefits, and risks of immunotherapies in the CNS compartment - Research topics include blood brain barrier penetration, compartmentalized viral dynamics, immune-mediated effects, neurotoxicity, and neuroinflammation - Unique/Notable Requirements: - No specific OEMs or vendors are named; this is a research grant opportunity - Open to a wide range of applicants: nonprofits, educational institutions, government entities, and businesses - Utilizes the R21/R33 activity code (biphasic grant mechanism) - Aims to support strategies for sustained virologic remission and improved neurologic/cognitive outcomes - Place of Performance: - National Institutes of Health (federal office) - No product part numbers or quantities are specified, as this is a research solicitation
Description
The National Institute of Mental Health (NIMH) is soliciting biphasic research applications to evaluate the impact of HIV immunotherapies on central nervous system (CNS) outcomes in people with HIV. The research aims to identify mechanisms, benefits, and risks associated with the use of these immunotherapies in the CNS compartment. The goal is to generate evidence to inform whether HIV immunotherapies can safely and effectively target CNS HIV persistence while minimizing neurotoxicity and neuroinflammation. This effort supports the development of strategies to achieve sustained virologic remission and improve long-term neurologic and cognitive outcomes in people with HIV.